ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2012
Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer.
Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.Cancers · 2024Review
- Novel Therapeutic Approaches Targeting Post-Translational Modifications in Lung Cancer.Pharmaceutics · 2023Review
- A Century of Fractionated Radiotherapy: How Mathematical Oncology Can Break the Rules.International journal of molecular sciences · 2022Review
- CAR Co-Operates With Integrins to Promote Lung Cancer Cell Adhesion and Invasion.Frontiers in oncology · 2022Article
- Making radiation therapy more effective in the era of precision medicine.Precision clinical medicine · 2020Article
- Co-Expression of Coxsackievirus/Adenovirus Receptors and Desmoglein 2 in Lung Adenocarcinoma: A Comprehensive Analysis of Bioinformatics and Tissue Microarrays.Journal of clinical medicine · 2020Article
- KIF22 coordinates CAR and EGFR dynamics to promote cancer cell proliferation.Science signaling · 2018Article
- Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.Molecular oncology · 2015Article
- An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.World journal of stem cells · 2014Review
- Therapy-resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2013Article
- Effects of heat stress on the expression of the coxsackievirus and adenovirus receptor in mouse skin keratinocytes.Experimental and therapeutic medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTreatment resistance resulting from the presence of cancer stem cells (CSCs) remains a challenge in cancer treatment. Little is known about possible markers of CSCs in treatment-resistant non-small cell lung cancer (NSCLC). We explored the coxsackie-adenovirus receptor (CAR) as one such marker of CSCs in models of treatment-resistant NSCLC. MATERIALS AND
methodsResistant H460 and A549 cell lines were established by repeated exposure to paclitaxel or fractionated radiation. CSC markers were measured by Western blotting and flow cytometry. We also established stable CAR-overexpressing and stable shRNA-CAR-knockdown cell lines and assessed their survival, invasiveness, and tumorigenic capabilities with clonogenic, telomerase, Matrigel, and tumor formation assays.
resultsCAR expression was associated with CSC phenotype both in vitro and in vivo. CAR-overexpressing cells were more treatment-resistant, self-renewing, and tumorigenic than were parental cells, and shRNA-mediated knockdown of CAR expression was sufficient to inhibit these functions. CAR expression also correlated with the epithelial-mesenchymal transition.
conclusionsWe showed for the first time that CAR is a marker of CSCs and may affect the activities of CSCs in treatment-resistant NSCLC. CAR may prove to be a target for CSC treatment and a predictor of treatment response in patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.